The first relatively long-term CAR T-cell trial follow-up data came out at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Speaking from the meeting, Tanya Siddiqi, MD, of the City of Hope National Medical Center, Duarte, CA, discusses the ZUMA-1 (NCT02348216) study of the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (axi-cel; KTE-C19). Dr Siddiqi discusses the long-term data thus far on remission, response durability and toxicity.
Follow-up CAR T-cell data so far
